Stockscreener 앱 받기
106.25
1.61%
1.68
시간 외 거래:
106.09
-0.16
-0.15%
Abbott Laboratories 주식(ABT)의 최신 뉴스
JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4? - Zacks Investment Research
Abbott To Spin Off $8.5B Nutrition Business Into Standalone Public Company - https://en.edairynews.com/
Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact - The Motley Fool
Abbott Laboratories (ABT) Sees $23.9 Million in Net ETF Buying on Monday - Yahoo Finance
Abbott Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 - www.marketscreener.com
Abbott: Demand Headwinds & Litigation Risks Priced-InSpin-Off Tailwinds Ahead (ABT) - Seeking Alpha
Argus Downgrades Abbott Laboratories to Hold From Buy - marketscreener.com
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Zacks Investment Research
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now? - Yahoo Finance
This Dividend King Just Announced Great News for Investors - The Motley Fool
This Dividend King Just Announced Great News for Investors - The Motley Fool
In Ga. District Court, Product Liability Claim Over Abbott Laboratories' Heart Valve Filed - Law.com
Abbott Laboratories: A New Growth Story Takes Shape (NYSE:ABT) - Seeking Alpha
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy? - The Motley Fool
No change to CG operations as Abbott announces plans to separate nutrition business - PinalCentral.com
What the $8.5B Abbott Nutrition spinoff means for Columbus - The Business Journals
Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device - GlobeNewswire Inc.
Abbott Laboratories announces a baby formula spinoff company - Marketplace.org
Abbott: 3 Key Takeaways for Long-Term Investors - The Motley Fool
Abbott Laboratories plans to spin off nutrition business, following years of tumult over infant formulas - Chicago Tribune
Abbott to Carve Out Nutrition Business Into Independent Company - WSJ
Pre-Markets in Green on Strong Earnings Results - Zacks Investment Research
Pre-Markets Up on Cooling Metrics, Decent Q3 Reports - Zacks Investment Research
Abbott Laboratories to spin off nutrition unit at centre of baby formula lawsuits - Financial Times
Abbott (ABT) Misses Q3 Earnings Estimates - Zacks Investment Research
Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.
Abbott cuts 2026 sales growth view, plans to spin off nutrition business - Reuters
Abbott Spins Off Embattled Business That Sells Baby Formula - Bloomberg
Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test - Yahoo Finance
Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock - Trefis
Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive? - Yahoo Finance
Kevin Warsh's Fed May Not Cut Rates Soon. That's Why This Dividend Stock Belongs in Your Portfolio. - The Motley Fool
Abbott Q3 preview: What to expect (ABT:NYSE) - Seeking Alpha
The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services - The Globe and Mail
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research
How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings - Benzinga
What iShares U.S. Medical Devices ETF (IHI) Sold: Abbott Leads on Friday - Yahoo Finance
Abbott schedules results. Abbott Laboratories stock trades 17.78 percent below its yearly high - ad-hoc-news.de
Key facts: Abbott Laboratories to Report Q3; Cologuard Plus CE Mark - TradingView
Abbott Wins Bid To Move Ex-Worker's Bias Suit To Illinois - Law360
2 Industries Beyond AI With Long-Term Demand Drivers for 2027 - Zacks Investment Research
UBS reiterates Buy on Abbott Labs stock, cites biosimilars pipeline - Investing.com
UBS reiterates Buy on Abbott Labs stock, cites biosimilars pipeline By Investing.com - Investing.com India
3 Wall Street Analysts See Intuitive Surgical Hitting $500. Here's the Bull Case. - The Motley Fool
Alert incorrectly tagged to Abbott Laboratories withdrawn - marketscreener.com
Abbott Laboratories expected to post earnings of $1.42 a shareEarnings Preview - TradingView
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings - Benzinga
Abbott Laboratories stock at EUR 93.23 ahead of the Xetra open - ad-hoc-news.de
Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. - The Motley Fool
Is Abbott Laboratories (ABT) Undervalued Following Product Launches And Growth Expectations? - Simply Wall Street
0.61%
0.14%
자본화:
|
볼륨(24시간):